🔎 Trials Near Me

Beranda › Limfoma › Nebraska

Uji klinis Limfoma di Nebraska

7 studi untuk Limfoma mencari peserta di lokasi di Nebraska.

Kota di Nebraska

Teks studi resmi (Bahasa Inggris)

Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma

  • University of Nebraska Medical Center, Omaha
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Agu 2026 · NCT05826535

Improving Cognitive Function in Older Adults Undergoing Stem Cell Transplant

  • University of Nebraska Medical Center, Omaha
Menerima peserta
Usia 19 ke atas · Semua jenis kelamin · Diperbarui 19 Agu 2026 · NCT04898790

A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies

  • University of Nebraska Medical Center, Omaha
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 17 Agu 2026 · NCT06528301

A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy

  • University of Nebraska Medical Center (UNMC), Omaha
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 4 Agu 2026 · NCT07188558

Study Using Prebiotics to Improve Gut Microbiome Diversity After Autologous Cellular Therapy

  • Unversity of Nebraska Medical Center, Omaha
Menerima peserta
Usia 19 ke atas · Semua jenis kelamin · Diperbarui 27 Jul 2026 · NCT05135351

CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)

  • Fred and Pamela Buffett Cancer Center, Omaha
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 16 Apr 2026 · NCT03328078

The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies

  • Oncology Hematology West P.C. dba Nebraska Cancer Specialists, Omaha
Menerima pesertaFase 1/2
Usia 12 hingga 95 · Semua jenis kelamin · Diperbarui 15 Apr 2026 · NCT04329728

Dari ClinicalTrials.gov, data diambil 4 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.